• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 8-K/A filed by AVROBIO Inc.

    6/18/24 11:51:59 AM ET
    $AVRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVRO alert in real time by email
    Form 8-K/A
    true 0001681087 0001681087 2024-06-14 2024-06-14

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K/A

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 14, 2024

     

     

    AVROBIO, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38537   81-0710585

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    One Broadway

    14th Floor

    Cambridge, MA 02142

    (Address of principal executive offices, including zip code)

    (617) 914-8420

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   AVRO   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    This Amendment to Form 8-K filed on June 14, 2024 notifies investors that the closing of the Merger (as defined below) that was previously anticipated to take place on or around June 18, 2024, is now anticipated to take place on or around June 20, 2024.

    As previously disclosed, on January 30, 2024, AVROBIO, Inc., a Delaware corporation (“AVRO” or the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among AVRO, Alpine Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of AVRO (“Merger Sub”), and Tectonic Therapeutic, Inc., a Delaware corporation (“Tectonic”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Tectonic (the “Merger”), with Tectonic continuing as a wholly owned subsidiary of AVRO and the surviving corporation of the Merger.

     

    Item 8.01

    Other Events

    In connection with the Merger, AVRO held a special meeting of its stockholders on June 11, 2024 (the “Special Meeting”), at which AVRO’s stockholders approved effecting a reverse stock split of AVRO’s issued common stock at a ratio in the range between 1:3 and 1:30, inclusive, with the final ratio and effectiveness of all other ratios of such amendment and the abandonment of such amendment to be mutually agreed by the board of directors of AVRO and the board of directors of Tectonic prior to the effective time (the “Reverse Stock Split”). AVRO’s board of directors previously approved, subject to AVRO’s stockholder approval of the Reverse Stock Split at the Special Meeting, a final ratio of 1-for-12 for the Reverse Stock Split.

    The closing of the Merger is anticipated to take place on or around June 20, 2024. On June 20, 2024, prior to the closing of the Merger, AVRO will file a certificate of amendment to AVRO’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, with an effective time of 4:00 p.m. Eastern Time on June 20, 2024 (the “Effective Time”).

    As of the Effective Time, each 12 shares of AVRO common stock, par value $0.0001, per share of AVRO (“Common Stock”) outstanding immediately prior to the Effective Time will be combined and reclassified, automatically and without any action on the part of AVRO or its stockholders, into one new share of Common Stock. No fractional shares of Common Stock will be issued as a result of the Reverse Stock Split. Instead, if upon aggregating all of the shares of Common Stock held by a record holder immediately following the Reverse Stock Split such holder would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, the Company shall pay in cash (without interest) to each such holder an amount equal to the product of such resulting fractional interest in one share of Common Stock multiplied by the closing trading price on the Nasdaq Stock Market LLC of a share of Common Stock on the last trading day immediately prior to the date on which the Effective Time occurs (with such price proportionately adjusted to give effect to the Reverse Stock Split).

    The Common Stock will commence trading on a split-adjusted basis, under the ticker symbol “TECX,” at the open of trading on June 21, 2024, at which time the Common Stock will be represented by a new CUSIP number 878972108. The par value per share of the Common Stock will remain unchanged.

    In addition, effective as of the Effective Time and as a result of the Reverse Stock Split, proportionate adjustments will be made in accordance with the terms of the Amended and Restated 2015 Stock Option and Grant Plan, 2018 Stock Option and Incentive Plan, 2018 Employee Stock Purchase Plan, 2019 Inducement Plan, and 2020 Inducement Plan, each, as amended from time to time (collectively, the “Plans”), with respect to the number of shares subject to outstanding equity awards, the per-share exercise or purchase price (if any) with respect to those awards, and the number of shares of Common Stock reserved for future issuance under the Plans.

    Forward-Looking Statements

    This Current Report on Form 8-K and the exhibits filed or furnished herewith contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the Merger or Reverse Stock Split; the combined company’s listing on Nasdaq after the closing of the proposed Merger


    (the “Closing”); expectations regarding the ownership structure of the combined company; the anticipated timing of the Closing; and other statements that are not historical fact. All statements other than statements of historical fact contained in this Current Report on Form 8-K and the exhibits filed or furnished herewith are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting AVRO, Tectonic, the Merger or the private placement financings will be those that have been anticipated.

    Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond AVRO’s control. AVRO’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to the risk that the conditions to the Closing are not satisfied. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in AVRO’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 14, 2024, subsequent Quarterly Reports on Form 10-Q filed with the SEC, as well as the final prospectus on Form 424(b)(3) filed with the SEC on May 3, 2024, and in other filings that AVRO makes and will make with the SEC in connection with the proposed Merger. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. AVRO expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. This Current Report on Form 8-K and the exhibits filed or furnished herewith do not purport to summarize all of the conditions, risks and other attributes of an investment in AVRO or Tectonic.

    No Offer or Solicitation

    This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, and otherwise in accordance with applicable law.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        AVROBIO, INC.
    Date: June 18, 2024     By:  

    /s/ Erik Ostrowski

          Erik Ostrowski
          President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer
    Get the next $AVRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVRO

    DatePrice TargetRatingAnalyst
    12/18/2023Buy → Neutral
    Mizuho
    1/6/2022$28.00 → $6.00Buy
    Mizuho
    1/5/2022$22.00 → $6.00Overweight
    Barclays
    1/5/2022$7.00 → $3.00Equal-Weight
    Morgan Stanley
    1/5/2022Buy → Neutral
    BTIG
    1/5/2022$28.00 → $8.00Buy
    Needham
    11/19/2021$24.00 → $7.00Overweight → Equal-Weight
    Morgan Stanley
    10/12/2021$27.00 → $25.00Overweight
    Morgan Stanley
    More analyst ratings

    $AVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

      Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and topline Phase 1B data expected in 2025 Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fu

      3/26/24 7:06:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Participation at Investor Conferences in March

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March: TD Cowen 44th Annual Health Care Conference being held in Boston on March 4 – 6 Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13 The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink rep

      2/27/24 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Former 10% owner of AVROBIO Leonard Braden Michael acquired 433,688 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/25/24 1:42:11 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donenberg Phillip B.

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:37:33 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vitorovic Stefan was granted 1,028,674 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:35:35 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    SEC Filings

    See more
    • AVROBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/25/24 9:52:20 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/20/24 4:25:03 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 8-K/A filed by AVROBIO Inc.

      8-K/A - AVROBIO, Inc. (0001681087) (Filer)

      6/18/24 11:51:59 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVROBIO downgraded by Mizuho

      Mizuho downgraded AVROBIO from Buy to Neutral

      12/18/23 8:06:56 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho reiterated coverage on Avrobio with a new price target

      Mizuho reiterated coverage of Avrobio with a rating of Buy and set a new price target of $6.00 from $28.00 previously

      1/6/22 6:59:42 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on Avrobio with a new price target

      Barclays reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $6.00 from $22.00 previously

      1/5/22 9:51:19 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Leonard Braden Michael bought $971,493 worth of shares (766,635 units at $1.27) (SEC Form 4)

      4 - AVROBIO, Inc. (0001681087) (Issuer)

      5/15/24 11:21:34 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO and Tectonic Therapeutic Announce Merger

      Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to advance lead asset TX45, a potential best-in-class Fc-relaxin fusion protein, through multiple clinical data catalysts Tectonic's first two programs address indications with high unmet need and no approved therapies Companies to host joint webcast to

      1/30/24 8:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

      On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated Announced appointment of current CFO Erik Ostrowski as interim CEO AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a l

      5/11/23 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Financials

    Live finance-specific insights

    See more
    • AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

      Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned for 2022; third patient dosed in Phase 1/2 clinical trial Regulatory interactions planned in 2022 to inform clinical development and registration strategies for programs in Gaucher disease, cystinosis, Hunter syndrome and Pompe disease Strong balance sheet with cash runway into Q1 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li

      3/17/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

      Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no adverse events related to drug product to date Clinical proof-of-concept in adult patients lays groundwork for AVROBIO-sponsored trial planned to begin in 2023 Analyst and investor conference call scheduled for today at 8:00 a.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported

      2/9/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

      Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as we

      1/27/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/26/24 8:00:02 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/25/24 4:23:25 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by AVROBIO Inc. (Amendment)

      SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)

      5/21/24 10:01:24 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care